Brief: Intensity Therapeutics, Inc. And The Swiss Group For Clinical Cancer Research SAKK Announce The First Patient Dosed In The Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
31/10/2024 13:11
Oct 31 (Reuters) - Intensity Therapeutics Inc INTS.O :
* INTENSITY THERAPEUTICS, INC. AND THE SWISS GROUP FOR
CLINICAL
CANCER RESEARCH SAKK ANNOUNCE THE FIRST PATIENT DOSED IN THE
RANDOMIZED, PRESURGICAL TRIPLE NEGATIVE BREAST CANCER PHASE 2
CLINICAL TRIAL (INVINCIBLE-4 / SAKK 66/22)
Source text: ID:nPn5HG7mna
Further company coverage: INTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intensity Therapeutics
See all newsIntensity Therapeutics Q2 net loss widens as R&D costs rise
Brief: Intensity Therapeutics Q2 Operating Income USD -3.084 Million
Intensity Therapeutics Q1 net loss narrows on lower R&D costs
Brief: Intensity Therapeutics Q1 Operating Income USD -2.526 Million
Brief: Intensity Therapeutics Inc - Increases ATM Offering Capacity To $60 Million On March 23, 2026 - SEC Filing